Signed but Not Understood: The Comprehension Crisis Undermining Informed Consent in US Clinical Trials

The signed consent form occupies a foundational position in clinical research ethics. It represents, at least in principle, the moment a prospective trial participant freely and knowingly agrees to accept the risks and obligations of enrollment. Yet a growing body of evidence suggests that this document—far from constituting genuine informed agreement—frequently functions as a legal instrument that satisfies regulatory requirements while failing the very individuals it is designed to protect.

For investigators, institutional review boards, and sponsors operating within the US clinical trial infrastructure, this is no longer a peripheral concern. The comprehension gap embedded in standard consent practices is now generating measurable consequences: elevated dropout rates, distorted adverse event reporting, eroding participant trust, and an increasingly contested liability landscape.

The Readability Problem in Plain Sight

Multiple independent analyses of informed consent documents used in US clinical trials have found that the average reading level of these forms falls between the 10th and 14th grade—well above the eighth-grade benchmark that federal health literacy guidelines recommend for patient-facing materials. The National Institutes of Health and the Food and Drug Administration have both issued guidance encouraging plain language in consent documentation, yet neither agency has established enforceable readability standards tied to IRB approval or trial registration.

The practical consequence is that consent forms continue to be drafted primarily by legal and regulatory affairs teams whose primary objective is institutional protection rather than participant comprehension. Technical terminology, passive sentence constructions, and dense procedural language persist across documents that patients are typically given limited time to review—often in a clinical setting, under time pressure, and frequently without an opportunity to consult family members or personal physicians.

The demographic mismatch compounds this structural problem. US trial populations increasingly include participants from lower-income communities, non-native English speakers, and older adults with age-related cognitive considerations—precisely the groups least likely to navigate documents calibrated for a college-educated reader. Meanwhile, diversity enrollment initiatives, while laudable in intent, have not been systematically paired with corresponding investments in consent accessibility.

What Participants Actually Understand

Comprehension testing studies—using instruments such as the Quality of Informed Consent (QuIC) questionnaire and the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC)—have repeatedly documented that a substantial proportion of enrolled trial participants cannot accurately describe the purpose of the study they have joined, the nature of randomization, or their right to withdraw without penalty.

In one frequently cited multi-site study, fewer than half of enrolled participants correctly identified that they might receive a placebo. In oncology trials, where the stakes of misunderstanding are particularly acute, comprehension deficits have been documented even among participants with higher educational attainment—suggesting that emotional distress and the complexity of treatment protocols introduce comprehension barriers independent of literacy level.

These findings carry direct implications for the quality of data generated by trials. A participant who does not fully understand what symptoms to report, or who interprets normal treatment-related discomfort as a reportable adverse event because the consent form failed to adequately distinguish between expected and unexpected effects, introduces noise into safety datasets. Conversely, participants who misunderstand their right to withdraw may continue enrollment despite experiencing outcomes they would otherwise have reported, suppressing adverse event data in ways that are difficult to detect during standard monitoring.

The Liability Terrain Is Shifting

The legal dimension of consent comprehension has historically been adjudicated under a relatively forgiving standard: if a patient signed, and the form disclosed the relevant risks, institutional liability was generally considered addressed. That framework is under increasing pressure.

Several recent cases before US federal and state courts have examined whether disclosure alone satisfies the ethical and legal standard of informed consent when there is documented evidence that the consenting individual lacked the capacity to understand what was disclosed. Plaintiff attorneys in clinical trial litigation are beginning to introduce comprehension testing data and readability analyses as evidence that consent was procedurally but not substantively valid—a distinction that courts are showing growing willingness to entertain.

Institutional review boards, which bear primary responsibility for evaluating consent documents before trial initiation, are also facing renewed scrutiny. Critics argue that IRB review of consent materials has become largely pro forma—focused on the presence of required disclosure elements rather than on whether the document achieves actual comprehension in the intended population. Some bioethicists have called for mandatory comprehension testing as a condition of IRB approval, a proposal that has gained traction in academic literature but has yet to reach regulatory implementation.

Toward Measurable Consent Quality

A small but significant number of research institutions have begun treating consent comprehension as a measurable quality indicator rather than an assumed outcome of document delivery. These programs incorporate teach-back methodology—requiring study coordinators to verify understanding through participant explanation rather than passive acknowledgment—and use multimedia consent tools, including video-based explanations and interactive digital platforms, to supplement written documents.

The evidence supporting these interventions is encouraging. Studies comparing standard written consent with enhanced comprehension protocols have demonstrated statistically significant improvements in participant understanding of study purpose, risk profiles, and voluntary participation rights. Importantly, some investigators have reported that enhanced consent processes are associated with improved retention rates and more consistent adverse event reporting—outcomes with direct implications for data quality and trial validity.

Nevertheless, adoption remains uneven. Enhanced consent methodologies require additional staff time, technological investment, and protocol modifications that many sponsors and sites are reluctant to absorb outside of regulatory compulsion. Until comprehension metrics are incorporated into trial quality frameworks—alongside conventional indicators such as protocol deviation rates and data query volumes—institutional incentives will continue to favor efficiency over understanding.

Reframing Consent as a Research Quality Variable

The prevailing tendency to treat informed consent as an ethical and legal obligation separate from scientific methodology has obscured its direct relevance to data integrity. If participants do not understand what they are agreeing to, what they are expected to report, or what their enrollment entails, the behavioral data they generate is compromised at the source.

This reframing—consent comprehension as a research quality variable rather than merely an ethical formality—offers a pragmatic argument for reform that extends beyond moral obligation. Sponsors and investigators whose primary concerns are trial validity and regulatory approval have concrete, data-driven reasons to care whether participants actually understand their consent documents.

Regulatory agencies, particularly the FDA in its oversight of investigational new drug applications and the Office for Human Research Protections in its stewardship of the Common Rule, are positioned to accelerate this shift by establishing enforceable readability thresholds, requiring documentation of comprehension verification, and incorporating consent quality into inspection frameworks.

Until that accountability structure exists, the signed consent form will continue to function as what it too often already is: a document that protects institutions while leaving participants navigating a process they were never genuinely equipped to understand.